Pier Capital’s Esperion Therapeutics ESPR Stock Holding History

Pier Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-69,909	Closed	-$6.47M	–	119
2015 Q1	$6.47M	Buy	+69,909	New	+$4.51M	0.98%	67

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pier Capital's ESPR Position: Q2 2015 in Review

Pier Capital sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 69,909 shares — an estimated $6.47M sold.

Pier Capital first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $6.47M in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

Pier Capital reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
Pier Capital sold 69,909 Esperion Therapeutics shares in Q2 2015, an estimated $6.47M.
Pier Capital first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
Pier Capital's Esperion Therapeutics position peaked at $6.47M in Q1 2015.
151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Pier Capital's 13F filing for Q2 2015, filed 12 Aug 2015.